James E. Rothman has been appointed to the newly created position of chief scientific adviser at Amersham. He has served seven years on the company's scientific advisory board. Rothman will work with CEO William Castell and will sit on Amersham's
James E. Rothman has been appointed to the newly created position of chief scientific adviser at Amersham. He has served seven years on the company's scientific advisory board. Rothman will work with CEO William Castell and will sit on Amersham's Portfolio Committee, which has primary responsibility for recommending overall strategic direction of the company's research.
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.